Literature DB >> 9988691

Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members.

G Velasco1, A M Pendás, A Fueyo, V Knäuper, G Murphy, C López-Otín.   

Abstract

A cDNA encoding a new human matrix metalloproteinase (MMP), tentatively called MMP-23, has been cloned from an ovary cDNA library. This protein exhibits sequence similarity with MMPs, but displays a different domain structure. Thus, MMP-23 lacks a recognizable signal sequence and has a short prodomain, although it contains a single cysteine residue that can be part of the cysteine-switch mechanism operating for maintaining enzyme latency. The C-terminal domain is considerably shortened and shows no sequence similarity to hemopexin, whereas all human MMPs, with the exception of matrilysin, contain four hemopexin-like repeats. Furthermore, MMP-23 is devoid of structural features distinctive of the diverse MMP subclasses, including the specific residues located close to the zinc-binding site in collagenases, the transmembrane domain of membrane-type MMPs, or the fibronectin-like domain of gelatinases. Fluorescent in situ hybridization experiments showed that the human MMP-23 gene maps to 1p36, a location which differs from all MMP genes mapped to date. Recombinant MMP-23 produced in Escherichia coli exhibits low, but significant proteolytic activity against a synthetic substrate commonly used for assaying MMPs. Northern blot analysis demonstrated that MMP-23 is predominantly expressed in ovary, testis, and prostate, suggesting that this new MMP may play a specialized role in reproductive processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988691     DOI: 10.1074/jbc.274.8.4570

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 3.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

4.  A genomic analysis of rat proteases and protease inhibitors.

Authors:  Xose S Puente; Carlos López-Otín
Journal:  Genome Res       Date:  2004-04       Impact factor: 9.043

Review 5.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 6.  Reaching the melting point: Degradative enzymes and protease inhibitors involved in baculovirus infection and dissemination.

Authors:  Egide Ishimwe; Jeffrey J Hodgson; Rollie J Clem; A Lorena Passarelli
Journal:  Virology       Date:  2015-02-25       Impact factor: 3.616

Review 7.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

Review 8.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

Review 9.  Matrix metalloproteinase control of capillary morphogenesis.

Authors:  Cyrus M Ghajar; Steven C George; Andrew J Putnam
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

10.  Potassium channel modulation by a toxin domain in matrix metalloprotease 23.

Authors:  Srikant Rangaraju; Keith K Khoo; Zhi-Ping Feng; George Crossley; Daniel Nugent; Ilya Khaytin; Victor Chi; Cory Pham; Peter Calabresi; Michael W Pennington; Raymond S Norton; K George Chandy
Journal:  J Biol Chem       Date:  2009-12-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.